Navitor Pharmaceuticals is a biopharmaceutical company delving into the world of cellular metabolism signaling pathways. Their proprietary drug discovery platform focuses on mTORC1, which plays a critical role in protein synthesis and cellular growth. By targeting mTORC1, Navitor aims to develop therapeutics for a range of diseases with disruption in this signaling pathway, including depression, chronic kidney disease, heart failure, and some genetic disorders. Their proprietary platform allows Navitor to discover and develop small molecule drugs that selectively targets and modulates mTORC1. Navitor was founded in 2010 with headquarters located in Cambridge, MA.

Navitor Pharmaceuticals

Founded: 2014
Location: Cambridge, MA
Employee range: 11 - 50
Clinical stage: Clin1
Therapy area: Depression
Drug types: PSY, NPH, GEN, CVV, NEU
Lead product: NV-5138
Funding: $33M B Dec 2015, $23.5M A Jun 2014

Drug notes:

About:

Jobs: